Moeko Noguchi-Shinohara, Junji Komatsu, Kenjiro Ono
{"title":"用lecanemab治疗阿尔茨海默病的载脂蛋白E ε4纯合子女性的淀粉样蛋白相关影像学异常","authors":"Moeko Noguchi-Shinohara, Junji Komatsu, Kenjiro Ono","doi":"10.1111/cen3.12821","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Lecanemab (Leqembi®) is an anti-amyloid monoclonal antibody used for the treatment of Alzheimer's disease (AD). However, side effects may occur with lecanemab, including amyloid-related imaging abnormalities (ARIA), especially in patients with apolipoprotein E ε4 (<i>APOE4</i>) homozygous.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 69-year-old woman had a 2-year history of worsening memory symptoms and was diagnosed with mild cognitive impairment due to AD. Because she carries two copies of the E4 allele of <i>APOE</i>, her doctor did not recommend lecanemab treatment. However, she strongly desired lecanemab treatment and received four infusions of lecanemab. She had no symptoms or neurological abnormalities, but a head MRI before the fifth infusion showed moderate radiographic ARIA; therefore, she was admitted and treated with steroids. One month later, a head MRI showed the ARIA had disappeared.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The indications of lecanemab treatment for patients with <i>APOE4</i> homozygous must be carefully considered due to the higher risk of ARIA.</p>\n </section>\n </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 3","pages":"254-257"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amyloid-related imaging abnormalities in a woman with apolipoprotein E ε4 homozygotes treated with lecanemab for Alzheimer's disease\",\"authors\":\"Moeko Noguchi-Shinohara, Junji Komatsu, Kenjiro Ono\",\"doi\":\"10.1111/cen3.12821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Lecanemab (Leqembi®) is an anti-amyloid monoclonal antibody used for the treatment of Alzheimer's disease (AD). However, side effects may occur with lecanemab, including amyloid-related imaging abnormalities (ARIA), especially in patients with apolipoprotein E ε4 (<i>APOE4</i>) homozygous.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case Presentation</h3>\\n \\n <p>A 69-year-old woman had a 2-year history of worsening memory symptoms and was diagnosed with mild cognitive impairment due to AD. Because she carries two copies of the E4 allele of <i>APOE</i>, her doctor did not recommend lecanemab treatment. However, she strongly desired lecanemab treatment and received four infusions of lecanemab. She had no symptoms or neurological abnormalities, but a head MRI before the fifth infusion showed moderate radiographic ARIA; therefore, she was admitted and treated with steroids. One month later, a head MRI showed the ARIA had disappeared.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The indications of lecanemab treatment for patients with <i>APOE4</i> homozygous must be carefully considered due to the higher risk of ARIA.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10193,\"journal\":{\"name\":\"Clinical and Experimental Neuroimmunology\",\"volume\":\"16 3\",\"pages\":\"254-257\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Neuroimmunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12821\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
Amyloid-related imaging abnormalities in a woman with apolipoprotein E ε4 homozygotes treated with lecanemab for Alzheimer's disease
Background
Lecanemab (Leqembi®) is an anti-amyloid monoclonal antibody used for the treatment of Alzheimer's disease (AD). However, side effects may occur with lecanemab, including amyloid-related imaging abnormalities (ARIA), especially in patients with apolipoprotein E ε4 (APOE4) homozygous.
Case Presentation
A 69-year-old woman had a 2-year history of worsening memory symptoms and was diagnosed with mild cognitive impairment due to AD. Because she carries two copies of the E4 allele of APOE, her doctor did not recommend lecanemab treatment. However, she strongly desired lecanemab treatment and received four infusions of lecanemab. She had no symptoms or neurological abnormalities, but a head MRI before the fifth infusion showed moderate radiographic ARIA; therefore, she was admitted and treated with steroids. One month later, a head MRI showed the ARIA had disappeared.
Conclusion
The indications of lecanemab treatment for patients with APOE4 homozygous must be carefully considered due to the higher risk of ARIA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
